An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer

This Phase I study is testing a new CAR-T cell therapy called C-CAR031 — an experimental treatment where a patient's own immune cells are genetically modified to recognize and attack cancer cells — for people with advanced squamous cell lung cancer that expresses a protein called GPC3. This is an early safety and dosing study. **You may be eligible if...** - You have confirmed advanced or metastatic squamous cell lung cancer (stage IIIB, IIIC, or IV) that cannot be surgically removed - Your tumor tests positive for the GPC3 protein - You have received up to three prior lines of treatment for your lung cancer and either progressed or could not tolerate them - Your heart's pumping function is normal (ejection fraction 50% or above) - Your lung function and blood counts are adequate **You may NOT be eligible if...** - Your cancer has a targetable driver mutation for which a standard targeted drug is recommended (e.g., EGFR, ALK) - You have had a prior CAR-T cell therapy or any GPC3-targeting treatment - You have had a splenectomy or organ transplant - You have active, uncontrolled lung disease, significant fluid around the lungs or heart, or cancer spreading to the brain or spinal cord - You have known severe allergies to the CAR-T product or its components Talk to your doctor to see if this trial is right for you.